Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluviral S/F Influenza Vaccine in Healthy Adults
NCT01389479Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2005
- Primary completion
- May 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated) in influenza (2 arms), sponsored by GSK. Primary endpoints: Number of subjects with solicited local and systemic reactogenicity symptoms at 3 days, Number of subjects reporting spontaneous adverse events at 42 days and 2 more. Started Jan 2005; status: completed.
02
Drugs
influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01389479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01389479.